MANTLE CELL LYMPHOMA – A REVIEW OF RESEARCH
Abstract
Mantle cell lymphoma remains a cancer with a high risk of recurrence, but advances in treatment are significantly changing the prognosis for patients. Molecularly targeted therapies, such as the combination of ibrutinib and venetoclax, as well as immunotherapy using CAR-T cells (chimeric antigen receptor T-cells), show high clinical efficacy and the potential for sustained remission. Research results indicate a significant prolongation of progression-free survival with an acceptable safety profile. Further development of therapeutic strategies should focus on personalising treatment, identifying response biomarkers and minimising adverse effects. These advances offer a real chance for long-term disease control.
The aim of this study is to evaluate the efficacy and safety of modern molecularly targeted and cellular therapies in the treatment of mantle cell lymphoma, with particular emphasis on their impact on remission duration, progression-free survival and the possibility of long-term disease control. The study aims to highlight the importance of individualising treatment, integrating different therapeutic methods and identifying biomarkers that can support a more precise clinical approach.
References
E. Silkenstedt , M. Dreyling To consolidate or not to consolidate: the role of autologous stem cell transplantation in mantle cell lymphoma (MCL). Hematology Am Soc Hematol Educ Program 2024; 2024 (1): 42–47. doi: https://doi.org/10.1182/hematology.2024000546
ESMO Clinical Practice Guidelines — Mantle Cell Lymphoma (current guidelines, ESMO/2024–2025).
Flinn, I. W., van der Jagt, R., Kahl, B., Wood, P., Hawkins, T., MacDonald, D., Simpson, D., Kolibaba, K., Issa, S., Chang, J., Trotman, J., Hallman, D., Chen, L., & Burke, J. M. (2019). First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 37(12), 984–991. https://doi.org/10.1200/JCO.18.00605
Handunnetti, S. M., Anderson, M. A., Burbury, K., Thompson, P. A., Burke, G., Bressel, M., Di Iulio, J., Hicks, R. J., Westerman, D., Lade, S., Pott, C., Agarwal, R., Koldej, R., Ritchie, D., Dreyling, M., Dawson, M. A., Dawson, S.-J., Seymour, J. F., Roberts, A. W., & Tam, K. S. (2024). Seven-year results of venetoclax and ibrutinib therapy in mantle cell lymphoma: Durable responses and treatment-free remissions. Blood, 144(8), 867–872. https://doi.org/10.1182/blood.2023023388
Herbaux C, Bret C, Bachy E, Bories P, Di Blasi R, Cuffel A, Gastinne T, Lamy T, Roussel M, Bouabdallah K, Beauvais D, Cartron G, Bay JO, Blaise D, Rubio MT, Mohty M, Le Bras F, Casasnovas O, Guy J, Guidez S, Llorente CC, Hermine O, La Rochelle LD, Carras S, Guffroy B, Caillat-Zucman S, Houot R, Le Gouill S. Brexucabtagene autoleucel in relapsed or refractory mantle cell lymphoma, intention-to-treat use in the DESCAR-T registry. Haematologica. 2024 Nov 1;109(11):3745-3750. doi: 10.3324/haematol.2023.284786. PMID: 38899352; PMCID: PMC11532701.
Kamdar M, Li H, Chen RW, Rimsza LM, Leblanc ML, Fenske TS, Shea TC, Barr PM, Phillips TJ, Leonard JP, Kahl BS, Friedberg JW, Smith SM. Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma. Blood Adv. 2019 Oct 22;3(20):3132-3135. doi: 10.1182/bloodadvances.2019000526. PMID: 31648328; PMCID: PMC6849956.
Song Y, et al. Zanubrutinib in relapsed/refractory mantle cell lymphoma — Long-term registration results. Blood / Phase II publication and analysis. 2022.
Swerdlow SH, Campo E, Harris NL et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th Edition. Lyon: International Agency for Research on Cancer (IARC); 2017.
Tam CS, O'Connor OA, et al. (Ibrutinib studies in relapsed/refractory MCL) N Engl J Med / key phase II studies.
Tam, C. S., Anderson, M. A., Pott, C., Agarwal, R., Handunnetti, S., Hicks, R. J., Burbury, K., & Roberts, A. W. (2018). Ibrutinib and venetoclax for mantle-cell lymphoma. The New England Journal of Medicine, 378(13), 1211–1223. https://doi.org/10.1056/NEJMoa1715519
Wang M., et al. Ibrutinib + venetoclax in MCL — long-term/new results and randomizations (Lancet Oncology; 2024–2025 reports).
Wang M., et al. Three-year follow-up of KTE-X19 in relapsed/refractory MCL (ZUMA-2 follow-up / J Clin Oncol 2023).
Wang M., Munoz J., Goy A., et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382:1331–1342. (ZUMA-2 pivotal).
Wang, M., Munoz, J., Goy, A., Locke, F. L., Jacobson, C. A., Hill, B. T., Timmerman, J. M., Holmes, H., Jaglowski, S., Flinn, I. W., McSweeney, P. A., Miklos, D. B., Pagel, J. M., Kersten, M. J., Milpied, N., Fung, H., Topp, M. S., Houot, R., Beitinjaneh, A., Peng, W., … Reagan, P. M. (2020). KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. The New England journal of medicine, 382(14), 1331–1342. https://doi.org/10.1056/NEJMoa1914347
Yang, P., Li, C., Liu, S., Wang, J., Chen, Y.-T., Zhang, W.-L., & Jing, H.-M. (2025). Results of treatment with BTK inhibitors and venetoclax with or without anti-CD20 monoclonal antibody in relapsed or refractory mantle cell lymphoma. Annals of Hematology, 104(4), 2361–2371. https://doi.org/10.1007/s00277-025-06379-x
Copyright (c) 2025 Hanna Pietruszewska, Katarzyna Kleszczewska, Agnieszka Pruska, Natalia Senatorska, Julia Rarok, Daria Godlewska, Monika Banaszek, Agata Panfil, Julia Błocka, Agata Lurka
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
